Foresee Pharmaceuticals Co., Ltd.

6576

TW0006576002

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
95 ^TWD	-0.11%		+1.50%	-1.25%

Apr. 01	Foresee Pharmaceuticals Receives Positive Recommendation from Data and Safety Monitoring Board to Continue the Casppian Study	CI
Mar. 28	Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Foresee Pharmaceuticals Co., Ltd. Announces Appointment of Ben Liu as Member to the Compensation Committee

August 14, 2023 at 04:06 am EDT

Foresee Pharmaceuticals Co., Ltd. announced appointment of Ben Liu, Partner, InfoShare Tech Law Office as a Member to the Compensation Committee with effect from August 14, 2023.

Latest news about Foresee Pharmaceuticals Co., Ltd.

Foresee Pharmaceuticals Receives Positive Recommendation from Data and Safety Monitoring Board to Continue the Casppian Study	Apr. 01	CI
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Foresee Pharmaceuticals Co., Ltd. Announces Executive Changes, Effective March 31, 2024	Mar. 15	CI
Foresee Pharmaceuticals Co., Ltd. Obtains the Official Pharmaceutical License of CAMCEVI 42 Mg from the Ministry of Health and Welfare in Taiwan	Dec. 01	CI
Foresee Pharmaceuticals Co., Ltd. Announces Last Patient Enrolled in the China Registration Clinical Trial of Leuprolide Injectable Emulsion in Prostate Cancer Has Completed Treatment	Nov. 29	CI
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 10	CI
Foresee Pharmaceuticals Co., Ltd. Submits Phase 3 IND (Investigational New Drug) Application to China NMPA	23-10-16	CI
Foresee Pharmaceuticals Announces First Patient Dosed in the Casppian, Phase 3 Clinical Trial of Leuprolide (FP-001) Injectable Emulsion, 42 mg for the Treatment of Central Precocious Puberty Patients	23-10-13	CI
Foresee Pharmaceuticals to Present Phase 1/2 Fanconi Anemia Clinical Study Design for its ALDH2 Activator FP-045 at the Fanconi Anemia Research Fund 2023 Scientific Symposium	23-09-30	CI
Foresee Pharmaceuticals Announces FDA Orange Book Listing of New U.S. Patent for Camcevi®, Extending Patent Protection to 2039	23-08-29	CI
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Foresee Pharmaceuticals Co., Ltd. Announces Appointment of Ben Liu as Member to the Compensation Committee	23-08-14	CI
Foresee Pharmaceuticals to Present Allergic Asthma Study at European Medical Conference	23-07-26	MT
Foresee Pharmaceuticals Co., Ltd. Appoints Ben Liu as Audit Committee Member	23-06-01	CI
Foresee Pharmaceuticals Co., Ltd. Announces Appointment of Ben Liu as Independent Director	23-06-01	CI
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Foresee Pharmaceuticals Co., Ltd. Announces Executive Changes	23-04-14	CI
Foresee Pharmaceuticals Co., Ltd. Announces the Primary Endpoint Data FP-025 in an Allergic Asthma Phase 2A Trial	23-04-03	CI
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-23	CI
Foresee Pharmaceuticals Co., Ltd. Announces Change of its Senior Vice President of Clinical Development and Program Lead	23-02-17	CI
Foresee Pharmaceuticals Co., Ltd. Receives Approval from China NMPA for the Application of Phase 3 IND for FP-001 42 mg in Patients with Central Precocious Puberty	23-01-16	CI
Foresee Pharmaceuticals Co., Ltd. Receives Approval from Taiwan FDA for the Application of Phase 3 IND for FP-001 42 Mgin Patients with Central Precocious Puberty	23-01-01	CI
Foresee Pharmaceuticals Co., Ltd. Announces the Submission of A Phase 3 Clinical Trial Application for FP-001 42 Mg in Patients with Central Precocious Puberty to EMA	22-12-23	CI
Foresee Pharmaceuticals Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-11	CI
Foresee Pharmaceuticals Co., Ltd. Announces Phase 3 Clinical Trial Application for Fp-00142 Mg in Patients with Central Precocious Puberty Has Been Accepted by China NMPA for Substantial Review	22-11-02	CI

Chart Foresee Pharmaceuticals Co., Ltd.

Duration

Period

More charts

Foresee Pharmaceuticals Co., Ltd. is a Taiwan-based company mainly engaged in the research and development of new pharmaceuticals. The Company's main products include prostate cancer treatment product FP-001 and asthmatic/chronic obstructive pulmonary disease treatment product FP-025. It also engages in new pharmaceuticals clinic trial business.

Sector

Biotechnology & Medical Research

Calendar

2024-05-09 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Foresee Pharmaceuticals Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

95 TWD

Average target price

153 TWD

Spread / Average Target

+61.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
FORESEE PHARMACEUTICALS CO., LTD.	-1.25%	396M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research